<DOC>
	<DOCNO>NCT00394277</DOCNO>
	<brief_summary>This 4-arm study compare efficacy safety PEGASYS induction maintenance dosing , versus standard fix dose combination Copegus , efficacy safety high dose versus standard dose Copegus combination PEGASYS . Patients chronic hepatitis C ( CHC ) genotype 1 infection high viral titer , baseline body weight ≥85 kg , randomize one 4 group , receive one following : ) PEGASYS 180 µg subcutaneously ( sc ) weekly plus Copegus 1200 mg orally ( po ) daily ; b ) PEGASYS 180 µg sc weekly plus Copegus 1400-1600 mg po daily ; c ) PEGASYS 360 µg sc weekly ( induction ) follow 180 µg sc weekly ( maintenance ) plus Copegus 1200 mg po daily ; ) PEGASYS 360 µg sc weekly ( induction ) follow 180 µg sc weekly ( maintenance ) plus Copegus 1400-1600 mg po daily . Following 48 week treatment , 24-week period treatment-free follow-up . The anticipated time study treatment 3-12 month , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Induction Dosing With PEGASYS ( Peginterferon Alfa-2a 40KD ) Plus Copegus Treatment-Naive Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient , ≥18 year age CHC infection , genotype 1 Hepatitis C virus ( HCV ) RNA ≥400,000 IU/mL Baseline body weight ≥85 kg Liver biopsy ( within 24 month first dose ) result consistent CHC Previous treatment interferon , ribavirin , viramidine , levovirin , HCV polymerase protease inhibitor Other form liver disease , include liver cancer Human immunodeficiency virus infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>